Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (5): 512-518.doi: 10.3969/j.issn.1000-6621.2018.05.014
• Original Articles • Previous Articles Next Articles
Fei-yong RAN,Lei FU,Bin WANG,Shao-chen GUO,Yu LU(),Xiao-you CHEN()
Received:
2018-03-15
Online:
2018-05-10
Published:
2018-06-12
Contact:
Yu LU,Xiao-you CHEN
E-mail:luyu4876@hotmail.com;chenxy1998@hotmail.com
Fei-yong RAN,Lei FU,Bin WANG,Shao-chen GUO,Yu LU,Xiao-you CHEN. Evaluation of the effect of vitamin D on adjuvant therapy in the Guinea Pig model of tuberculosis[J]. Chinese Journal of Antituberculosis, 2018, 40(5): 512-518. doi: 10.3969/j.issn.1000-6621.2018.05.014
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.05.014
组别 | 体质量(g, | 8周平均增加 体质量(g) | ||
---|---|---|---|---|
0周 | 4周 | 8周 | ||
空白对照组 | 513.30±49.85 | 639.64±87.02 | 720.82±101.2 | 207.52 |
VD组 | 487.60±16.04 | 602.98±23.04 | 682.37±38.30 | 194.77 |
VDH组 | 504.28±36.89 | 594.13±51.30 | 779.91±86.79 | 275.63 |
H-R组 | 493.70±27.16 | 586.90±58.89 | 649.36±63.01 | 155.66 |
H-R+VD组 | 464.84±38.75 | 541.49±39.29 | 677.85±29.83 | 213.01 |
H-R+VDH组 | 483.23±44.22 | 554.89±50.42 | 703.81±110.50 | 220.58 |
分组 | 肺脏活菌计数(lgCFU, | 脾脏活菌计数(lgCFU, | |||
---|---|---|---|---|---|
4周 | 8周 | 4周 | 8周 | ||
空白对照组 | 5.24±0.14 | 4.45±0.17 | 4.96±0.17 | 5.16±0.34 | |
VD组 | 5.19±0.28 | 4.39±0.20 | 5.39±0.32 | 4.75±0.03 | |
VDH组 | 4.94±0.05 | 4.40±0.14 | 5.85±0.29 | 4.77±0.12 | |
H-R组 | 4.98±0.26 | 3.73±0.23 | 4.02±0.03 | 2.26±0.24 | |
H-R+VD组 | 4.88±0.05 | 3.36±0.43 | 2.36±0.10 | 2.14±0.20 | |
H-R+VDH组 | 4.39±0.11 | 3.21±0.23 | 2.30±0.43 | - |
[1] | World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] | World Health Organization . The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva:World Health Organization, 2013. |
[3] |
Fox GJ, Menzies D . A Review of the Evidence for Using Bedaquiline (TMC207)to Treat Multi—Drug Resistant Tuberculosis. Infect Dis Ther, 2013,2(2):123-144.
doi: 10.1007/s40121-013-0009-3 URL |
[4] | World Health Organization . Interim policy guidance for the use of delamanid in the treatment of MDR-TB. Geneva: World Health Organization, 2014. |
[5] |
Gler M, Skripconoka V, Sanche-Garavito E , et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012,366(23):2151-2160.
doi: 10.1056/NEJMoa1112433 URL pmid: 22670901 |
[6] |
Charpy J, Dowling GB . Vitamin D in cutaneous tuberculosis. Lancet, 1947,2(6472):398.
doi: 10.1590/abd1806-4841.20142998 URL pmid: 20263553 |
[7] |
Daley P, Jagannathan V, John KR , et al. Adjunctive vitamin D for treatment of active tuberculosis in India:a randomised,double-blind,placebo-controlled trial. Lancet Infect Dis, 2015,15(5):528-534.
doi: 10.1016/S1473-3099(15)70053-8 URL |
[8] |
Tukvadze N, Sanikidze E, Kipiani M , et al. High-dose vitamin D3 in adults with pulmonary tuberculosis:a double-blind randomized controlled trial. Am J Clin Nutr, 2015,102(5):1059-1069.
doi: 10.3945/ajcn.115.113886 URL |
[9] |
Ralph AP, Waramori G, Pontororing GJ , et al. L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis:A Randomised,Double-Blind,Placebo-Controlled Trial. PLoS One, 2013,8(8):e70032.
doi: 10.1371/journal.pone.0070032 URL |
[10] |
Salahuddin N, Ali F, Hasan Z , et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized,placebo-controlled,clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect Dis, 2013,13:22.
doi: 10.1186/1471-2334-13-22 URL |
[11] |
Mily A, Rekha RS, Kamal SMM , et al. Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis:A Randomized Controlled Trial. PLoS One, 2015,10(9):e0138340.
doi: 10.1371/journal.pone.0138340 URL |
[12] | McCullough PJ, Lehrer DS . Vitamin D,cod liver oil,sunshine, and phototherapy:Safe,effective and forgotten tools for treating and curing tuberculosis infections-A comprehensive review. J Steroid Biochem Mol Biol, 2017,177:21-29. |
[13] |
Pierrot-Deseilligny C, Souberbielle JC . Vitamin D and multiple sclerosis:An update. Mult Scler Relat Disord, 2017,14:35-45.
doi: 10.15586/codon.multiplesclerosis.2017.ch5 URL |
[14] |
Luong KV, Nguyen LT, Nguyen DN . The role of vitamin D in protecting type 1 diabetes mellitus. Diabetes Metab Res Rev, 2005,21(4):338-346.
doi: 10.1007/s11661-999-0313-4 URL pmid: 15852446 |
[15] |
Tagliabue E, Raimondi S, Gandini S. Vitamin D, Cancer Risk , and Mortality. Adv Food Nutr Res, 2015,75:1-52.
doi: 10.1016/bs.afnr.2015.06.003 URL |
[16] |
Abe E, Miyaura C, Sakaqami H , et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA, 1981,78(8):4990-4994.
doi: 10.1073/pnas.78.8.4990 URL |
[17] |
Abe E, Miyaura C, Tanaka H , et al. 1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci USA, 1983,80(18):5583-5587.
doi: 10.1073/pnas.80.18.5583 URL |
[18] | Koeffler HP, Amatruda T, Ikekawa N , et al. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25 dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res, 1984,44(12 Pt1):5624-5628. |
[19] |
Chesdachai S, Zughaier SM, Hao L , et al. The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages. J Clin Transl Endocrinol, 2016,6:23-29.
doi: 10.1016/j.jcte.2016.08.005 URL |
[20] |
Reich KM, Fedorak RN, Madsen K , et al. Vitamin D improves inflammatory bowel disease outcomes:Basic science and clinical review. World J Gastroenterol, 2014,20(17):4934-4947.
doi: 10.3748/wjg.v20.i17.4934 URL pmid: 4009525 |
[21] |
Cantorna MT, Snyder L, Lin YD , et al. Vitamin D and 1,25(OH)2D Regulation of T cells. Nutrients, 2015,7(4):3011-3021.
doi: 10.3390/nu7043011 URL pmid: 25912039 |
[22] |
Reeme AE, Robinson RT . Dietary Vitamin D3 Suppresses Pulmonary Immunopathology Associated with Late-Stage Tuberculosis in C3HeB/FeJ Mice. J Immunol, 2016,196(3):1293-1304.
doi: 10.4049/jimmunol.1500931 URL |
[23] |
Zhao X, Yuan Y, Lin Y , et al. Vitamin D status in tuberculosis patients with diabetes,prediabetes and normal blood glucose in China:a cross-sectional study. BMJ Open, 2017,7(9):e017557.
doi: 10.1136/bmjopen-2017-017557 URL |
[24] |
Huang L, Liu C, Liao G , et al. Vitamin D Receptor Gene FokI Polymorphism Contributes to Increasing the Risk of Tuberculosis:An Update Meta-Analysis. Medicine (Baltimore), 2015,94(51):e2256.
doi: 10.1097/MD.0000000000002256 URL pmid: 26705207 |
[25] |
Lee YH, Song GG . Vitamin D receptor gene FokI,TaqI,BsmI,and ApaI polymorphisms and susceptibility to pulmonary tuberculosis:a meta-analysis. Genet Mol Res, 2015,14(3):9118-9129.
doi: 10.4238/2015.August.7.21 URL |
[26] |
Cegielski P, Vernon A . Tuberculosis and vitamin D:what’s the rest of the story. Lancet Infect Dis, 2015,15(5):489-490.
doi: 10.1016/S1473-3099(15)70163-5 URL pmid: 25863560 |
[27] |
Orme IM, Ordway DJ . Mouse and guinea pig models of tuberculosis. Microbiol Spectr, 2016,4(4):1-2.
doi: 10.1128/microbiolspec.TBTB2-0002-2015 URL pmid: 27726797 |
[28] |
Sarathi P, Karethimmaiah H, Goel A . High-dose Vitamin D Supplementation Precipitating Hypercalcemic Crisis in Granulomatous Disorders. Indian J Endocrinol Metab, 2017,21(6):815-819.
doi: 10.4103/ijem.IJEM_577_16 URL |
[29] |
Rode AKO, Kongsbak M, HansenMM , et al. Vitamin D Counteracts Mycobacterium tuberculosis-Induced Cathelicidin Downregulation in Dendritic Cells and Allows Th1 Differentiation and IFNγ Secretion. Front Immunol, 2017,8:656.
doi: 10.3389/fimmu.2017.00656 URL |
[1] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[2] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[3] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[4] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[5] | DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831. |
[6] | SHENG Jie, ZHU Yang, Dilixiati·Abulizi , TANG Wei, GU Fu-ding, SONG Xing-hua. Individualized treatment of drug-resistant osteoarticular tuberculosis based on phenotypic and molecular drug susceptibility tests and its short-term effectiveness evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 838-844. |
[7] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[8] | ZHENG Ya-mei, XIE Tian, WU Zhuo-le, CHEN Yong-xing. Clinical value of triple-drug adjuvant therapy for tuberculous pleurisy via chest wall ultrasound [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 695-700. |
[9] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[10] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[11] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
[12] | ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365. |
[13] | ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379. |
[14] | YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384. |
[15] | CHEN Yan-mei,HUANG Xin-chun,SUN Qi,ZHANG Chen-chen,WEN Wen-pei,CHEN Liang. Analysis of drug resistance in patients with smear-negative and culture-positive pulmonary tuberculosis in Guangdong province in 2016 [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 272-275. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||